Dr Reddy’s recalls over 8,000 bottles of generic drug in US due to packaging error
时间:2024-06-26 12:38:55 阅读(143)
Dr Reddy’s Laboratories is recalling over 8,000 bottles of a generic medication used to prevent rejection of a transplanted organ from the US market due to a packaging error, according to the US Food & Drug Administration.
The Hyderabad-based drug major is recalling 8,280 bottles of Tacrolimus capsules from the US market for “presence of foreign tablets/capsules” in the affected lot.
The affected lot was produced at Dr Reddy’s Bachupally-based plant near Hyderabad.
New Jersey-based Dr Reddy’s Laboratories, Inc has initiated the nationwide (US) Class II recall on December 15, 2023.
As per the USFDA, a Class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
Dr Reddy’s had recalled 4,000 bottles of the same drug in March last year as well. The company had initiated the recall on February 8, 2023.
猜你喜欢
- upGrad records more than 65,000 graduates in CY2023; enrollments continue to increase
- Sebi amends rules; enhances disclosure requirements for certain FPIs
- Wall St Week Ahead-Retailers’ results may be next test for rally in U
- Sebi cancels registration of Brickwork Ratings; directs it to wind down operations in 6 months
- US Stocks- Wall Street set for subdued open after Fed-driven selloff
- Where is share market headed after Nifty closes below 18540, Bank Nifty below 44130; check support, resistance
- Wall Street set to extend bounce as inflation fears ease
- US Navy helicopters fire at Yemen’s Houthi rebels and kill several in latest Red Sea shipping attack
- SBI, Tata Steel among top 4 technical stocks to buy; Nifty pull-back rally may continue up to 18450